{"success":true,"data":{"pressRelease":{"id":"45700","rtpr_id":"nBw2NVmjKa","ticker":"RCUS","exchange":"NYSE","all_tickers":["RCUS"],"title":"Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference","author":"Business Wire","published_at":"2026-05-26T20:05:00.310Z","article_body":"Arcus Biosciences to Participate in the Goldman Sachs 47(th) Annual Global\nHealthcare Conference\n\nArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical\ncompany focused on developing differentiated molecules and combination\ntherapies for patients with cancer and inflammatory and autoimmune diseases,\nannounced that its management team will participate in a fireside chat at the\nupcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The\nfireside chat will take place on Tuesday, June 9(th), 2026, at 10:40am ET.\n\nA live webcast of the presentation will be available by visiting the\n“Investors & Media” section of the Arcus Biosciences website at\nwww.arcusbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arcusbio.com%2F&esheet=54542003&newsitemid=20260526060565&lan=en-US&anchor=www.arcusbio.com&index=1&md5=b04b3b3fea1516ed292ddbe43124400c)\n. A replay will be available following the live event.\n\nAbout Arcus Biosciences\n\nArcus Biosciences is a clinical-stage, global biopharmaceutical company\nfocused on developing differentiated molecules for the treatment of cancer and\ninflammatory and autoimmune diseases. In partnership with industry\ncollaborators, patients and physicians around the world, Arcus is expediting\nthe development of its late-stage portfolio of first- and/or best-in-class\nmedicines against well-characterized biological targets and pathways and\nstudying novel, biology-driven combinations that have the potential to help\npeople with cancer live longer. Founded in 2015, the company has advanced\nmultiple investigational medicines into registrational clinical trials\nincluding casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma,\nand quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For\nmore information about Arcus Biosciences’ clinical and preclinical programs,\nplease visit www.arcusbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arcusbio.com&esheet=54542003&newsitemid=20260526060565&lan=en-US&anchor=www.arcusbio.com&index=2&md5=a1ded3b25c6bfb4fe3ae922a7ea1fa2d)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260526060565/en/\n(https://www.businesswire.com/news/home/20260526060565/en/)\n\nInvestor & Media Inquiries \n\nHolli Kolkey\n\nVP of Corporate Affairs\n\n(650) 922-1269\n\nhkolkey@arcusbio.com (mailto:hkolkey@arcusbio.com)\n\nMaryam Bassiri\n\nDirector, Corporate Affairs\n\n(510) 406-8520\n\nmbassiri@arcusbio.com (mailto:mbassiri@arcusbio.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw2NVmjKa","title":"Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference","author":"Business Wire","ticker":"RCUS","created":"2026-05-26T20:05:00.310Z","tickers":["RCUS"],"exchange":"NYSE","article_body":"Arcus Biosciences to Participate in the Goldman Sachs 47(th) Annual Global\nHealthcare Conference\n\nArcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical\ncompany focused on developing differentiated molecules and combination\ntherapies for patients with cancer and inflammatory and autoimmune diseases,\nannounced that its management team will participate in a fireside chat at the\nupcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL. The\nfireside chat will take place on Tuesday, June 9(th), 2026, at 10:40am ET.\n\nA live webcast of the presentation will be available by visiting the\n“Investors & Media” section of the Arcus Biosciences website at\nwww.arcusbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arcusbio.com%2F&esheet=54542003&newsitemid=20260526060565&lan=en-US&anchor=www.arcusbio.com&index=1&md5=b04b3b3fea1516ed292ddbe43124400c)\n. A replay will be available following the live event.\n\nAbout Arcus Biosciences\n\nArcus Biosciences is a clinical-stage, global biopharmaceutical company\nfocused on developing differentiated molecules for the treatment of cancer and\ninflammatory and autoimmune diseases. In partnership with industry\ncollaborators, patients and physicians around the world, Arcus is expediting\nthe development of its late-stage portfolio of first- and/or best-in-class\nmedicines against well-characterized biological targets and pathways and\nstudying novel, biology-driven combinations that have the potential to help\npeople with cancer live longer. Founded in 2015, the company has advanced\nmultiple investigational medicines into registrational clinical trials\nincluding casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma,\nand quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For\nmore information about Arcus Biosciences’ clinical and preclinical programs,\nplease visit www.arcusbio.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.arcusbio.com&esheet=54542003&newsitemid=20260526060565&lan=en-US&anchor=www.arcusbio.com&index=2&md5=a1ded3b25c6bfb4fe3ae922a7ea1fa2d)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260526060565/en/\n(https://www.businesswire.com/news/home/20260526060565/en/)\n\nInvestor & Media Inquiries \n\nHolli Kolkey\n\nVP of Corporate Affairs\n\n(650) 922-1269\n\nhkolkey@arcusbio.com (mailto:hkolkey@arcusbio.com)\n\nMaryam Bassiri\n\nDirector, Corporate Affairs\n\n(510) 406-8520\n\nmbassiri@arcusbio.com (mailto:mbassiri@arcusbio.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-26T20:05:00.371209588Z","server_sent_at_ms":1779825900371},"received_at":"2026-05-26T20:05:00.535Z","source_url":"https://www.businesswire.com/news/home/20260526060565/en/"},"analysis":{"id":"35129","press_release_id":"45700","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Arcus Biosciences management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.\n\nThe session is scheduled for June 9, 2026, at 10:40am ET in Miami Beach.\n\nA live webcast and replay will be available on the company's investor relations website.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance; no new data disclosed."},"keyFigures":{},"quotedText":"Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs Global Healthcare Conference in Miami Beach, FL.","namedEntities":{"people":[{"name":"Holli Kolkey","role":"VP of Corporate Affairs"},{"name":"Maryam Bassiri","role":"Director, Corporate Affairs"}],"products":["casdatifan","quemliclustat"],"companies":[{"name":"Arcus Biosciences","ticker":"RCUS"},{"name":"Goldman Sachs","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference participation announcement. No new clinical data, partnership, or financial disclosure is included. This is standard investor relations activity."},"tickerRelevance":{"others":[{"ticker":"GS","relevance":"conference host"}],"primary":"RCUS"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference_participation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Arcus Biosciences management will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.\n\nThe session is scheduled for June 9, 2026, at 10:40am ET in Miami Beach.\n\nA live webcast and replay will be available on the company's investor relations website.","key_figures":{},"named_entities":{"people":[{"name":"Holli Kolkey","role":"VP of Corporate Affairs"},{"name":"Maryam Bassiri","role":"Director, Corporate Affairs"}],"products":["casdatifan","quemliclustat"],"companies":[{"name":"Arcus Biosciences","ticker":"RCUS"},{"name":"Goldman Sachs","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-26T20:06:17.601Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference_participation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":22998,"modelName":"george-droid-qwen-72b"}}